Acceptance, benefits and effectiveness of the CoronaWarn-App (COVID-19 warning app)
Not yet recruiting
- Conditions
- COVID-19U07U99.0Emergency use of U07
- Registration Number
- DRKS00023685
- Lead Sponsor
- Medizinische Klinik 1 des Universitätsklinikums Erlangen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
Infection with SARS-coV-2
Exclusion Criteria
lack of ability to consent
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary endpoint is the benefit of the corona warning app regarding whether SARS-coV-2 positive patients use the app and were warned by it. <br>
- Secondary Outcome Measures
Name Time Method Correlation of app usage with general patient data. <br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does the CoronaWarn-App's digital contact tracing compare to manual methods in reducing SARS-CoV-2 transmission rates?
What biomarkers predict user compliance and effectiveness of the CoronaWarn-App in U07.1 pandemic scenarios?
What adverse events were reported in the DRKS00023685 observational study of the CoronaWarn-App's Bluetooth-based proximity alerts?
How does the CoronaWarn-App's adoption rate correlate with public health outcomes in U07.0 and U99.0 classified regions?
What molecular or behavioral mechanisms underlie the CoronaWarn-App's impact on asymptomatic SARS-CoV-2 spread according to DRKS00023685 data?